Treatment patterns in women with postmenopausal osteoporosis using abaloparatide: a real-world observational study
Authors' conclusion
Most patients completed treatment with abaloparatide as prescribed, and over half continued with an antiresorptive agent.
Study context
- Population
- Women with postmenopausal osteoporosis new to abaloparatide, regardless of osteoporosis treatment history; six academic and clinical practice settings, US (mean [SD] age 69.8 [7.4] years)
- Participants
- 173 women
- Outcome
- Real-world treatment patterns
Methodological detailsreal-world, multicentre (six academic and clinical practice settings, US), retrospective medical record review, 24 months of follow-up from 94.0% of patients; 6.0% had 12-24 months
- Real-world
- Multicentre (six academic and clinical practice settings, US)
- Retrospective medical record review
- 24 months of follow-up from 94.0% of patients; 6.0% had 12-24 months
Main finding
As reported in the abstract
Treatment patterns during follow-up
| Group | Value | ≥1 visit for osteoporosis management | Access to medication support program | Median duration of therapy | Discontinuation reason: financial | Discontinuation reason: tolerability | Transitioned to another osteoporosis medication | Median time to follow-on medication |
|---|---|---|---|---|---|---|---|---|
| Abaloparatide | 64.8% | 96.0% | 55.5% | 18.6 months | 31.2% | 22.8% | 82/162 (50.6%) | 21 days |
Abaloparatide
Value64.8%
≥1 visit for osteoporosis management96.0%
Access to medication support program55.5%
Median duration of therapy18.6 months
Discontinuation reason: financial31.2%
Discontinuation reason: tolerability22.8%
Transitioned to another osteoporosis medication82/162 (50.6%)
Median time to follow-on medication21 days
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Prior osteoporosis medication at abaloparatide initiation | Abaloparatide 78.6% |
| Time from discontinuation of prior osteoporosis medications to abaloparatide initiation | Abaloparatide Mean 1.7 (SD 3.2) years |
Original publication
Treatment patterns in women with postmenopausal osteoporosis using abaloparatide: a real-world observational study. Osteoporos Int. Published 24 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →